COMPOSITIONS CONTAINING MIXTURES OF FERMENTABLE FIBERS.

专利摘要:

公开号:BE1019755A3
申请号:E2010/0494
申请日:2010-08-18
公开日:2012-12-04
发明作者:Yann Dugenet；Heidi Jacobs；Christian Fougnies；Beatrice Morio；Veronique Coxam；Annick Bernalier
申请人:Cosucra Groupe Warcoing S A；Df3 Sas；
IPC主号:

专利说明:

Compositions containing mixtures of fermentable fibers Field of the invention
The present invention relates to compositions comprising fermentable fibers for preventing, reducing and / or treating inflammation. More particularly, the present invention relates to synergistic combinations of linear and branched fermentable fibers for modulating the inflammatory response of animals and humans after immune challenge.
Background of the Invention Inflammation is a complex biological reaction to harmful stimuli such as pathogens, damaged cells or irritants. The inflammatory response is an attempt by the body to restore and preserve homeostasis after invasion by an infectious agent, antigen challenge, or physical, chemical, or traumatic injury. Localized inflammation is located in a specific region and can be manifested by various symptoms, including redness, swelling, heat and pain. While the inflammatory response is generally considered to be a healthy response to injury, the immune system may exhibit an undesirable physiological response if it is not properly regulated. In this case, the body's normally protective immune system damages its own tissue by treating the healthy tissue as if it were infected or abnormal. Alternatively, in case of injury, the inflammatory response may be disproportionate to the threat causing the injury. If this is the case, the inflammatory reaction may cause more damage to the body than the agent itself would have done.
The inflammatory reaction was found to be partly composed of increased expression of pro-inflammatory cytokines and anti-inflammatory cytokines. Cytokines are biologically active, low molecular weight proteins involved in the coordination of immunological and inflammatory responses and in communication between specific immune cell populations. Several types of cells produce cytokines during inflammatory reactions, including neutrophils, monocytes, and lymphocytes. There are several mechanisms by which cytokines produced at inflammatory sites influence the inflammatory response. However, if an inflammatory response is not successfully countered by anti-inflammatory cytokines, uncontrolled systemic inflammation may occur. Unlike localized inflammation, systemic inflammation is diffused throughout the body. This type of inflammation may include localized inflammation at specific sites, but may also be associated with the general symptoms of "flu," including fever, chills, fatigue or loss of energy, headaches , loss of appetite and body aches. Systemic inflammation can cause protein degradation, catabolism and hypermetabolism. As a result, the structure and function of vital organs, such as muscle, heart, immune system and liver, may be compromised and may contribute to polyvisceral failure and mortality.
Although extraordinary progress has been made in understanding the mechanisms of systemic inflammation, the mortality rate due to this disorder remains too high to be acceptable.
It remains therefore necessary to develop compositions having better physiological and / or pharmacological and / or therapeutic activities for the prevention and / or treatment of inflammation. One of the objectives of the present invention is therefore to solve or improve at least one of the disadvantages of the prior art, or to propose a useful alternative.
Summary of the invention
The present inventors have surprisingly discovered that inulin and arabinoxylan, in particular a combination of partially hydrolysed inulin and arabinoxylan (AXOS), synergistically reduces, prevents and / or processes inflammation, particularly systemic inflammation.
Accordingly, the present invention relates to a composition comprising inulin and arabinoxylan for reducing, treating and / or preventing inflammation, particularly systemic inflammation. In particular, the present invention relates to a composition comprising inulin and arabinoxylan for use in reducing, preventing and / or treating inflammation, wherein said arabinoxylan is partially hydrolysed arabinoxylan and wherein the the ratio of said inulin to said arabinoxylan and / or said partially hydrolysed arabinoxylan is from 65% to 35% by weight to 90% to 10% by weight.
The present inventors have found that the present composition synergistically attenuates at the same time the increase of pro-inflammatory cytokines (such as TNF-α, IL-1 / IL-8, IL-12, IFN-γ). and the removal of anti-inflammatory cytokines (such as IL-10, IL-4, IL-13), after harmful stimuli such as lipopolysaccharide (LPS) challenge. The present composition comprising inulin and arabinoxylan or AXOS therefore has the advantage of improving resistance to stress, inflammation and / or immune challenge in humans and animals. Thus, the present invention also relates to a composition comprising inulin and arabinoxylan and / or partially hydrolysed arabinoxylan to attenuate at the same time the increase (elevation) of pro-inflammatory cytokines and the suppression of cytokines. anti-inflammatory drugs after challenge with LPS. In particular, the present invention also relates to a composition comprising inulin and arabinoxylan for use in attenuating both the increase (elevation) of pro-inflammatory cytokines and the suppression of anti-inflammatory cytokines after a LPS challenge, wherein said arabinoxylan is partially hydrolysed arabinoxylan and wherein the ratio of said inulin to said partially hydrolysed arabinoxylan and / or said arabinoxylan is from 65% to 35% by weight to 90% to 10% by weight. weight.
The present composition has also been shown to reduce the concentration of LPS in the blood and may therefore be used to reduce blood levels or levels of LPS. LPS can contribute to the initiation and development of inflammation, insulin resistance and / or fat storage. Therefore, the present invention offers the possibility of combating obesity, metabolic syndrome and / or type 2 diabetes. Thus, the present invention also relates to a composition comprising inulin and arabinoxylan and / or in particular, the present invention also relates to a composition comprising inulin and arabinoxylan and / or to or AXOS for use in the prevention, treatment and / or mitigation of obesity, metabolic syndrome and / or type 2 diabetes, wherein said arabinoxylan is partially hydrolysed arabinoxylan and in wherein the ratio of said inulin to said partially hydrolysed arabinoxylan and / or said arabinoxylan is from 65% to 35% by weight to 90% to 10% by weight.
Another aspect of the invention also relates to a composition comprising inulin and arabinoxylan, wherein the ratio of inulin / arabinoxylan is from 65% to 35% by weight to 95% to 5% by weight. In particular, the present invention also relates to a composition comprising inulin and arabinoxylan and / or partially hydrolysed arabinoxylan, wherein the ratio of said inulin to said arabinoxylan and / or said partially hydrolysed arabinoxylan is between 65 % / 35% by weight and 90% / 10% by weight. The present invention also relates to the use of said composition as a prebiotic.
The present invention also encompasses a food, a beverage or a food supplement comprising between 0.1 and 10 g of a composition according to the present invention by portion of said food, said beverage or said food supplement.
The present invention also contemplates the use of a composition according to the present invention as a food additive in the production of a food, a drink or a food supplement, which comprises between 0.1 and 10 g of said composition. per portion of said food, said beverage or said food supplement.
Description of figures
Figures 1A to 1E show graphs illustrating the effect of maltodextrin (placebo), AXOS and a mixture of 75% inulin and 25% AXOS according to the embodiment of the invention on the fermentation and inflammatory characteristics: where Figure 1A shows the effect on the amounts of acetate, propionate and butyrate, expressed in pmol / g of dry faeces, statistical differences between the groups: * p = 0 , 01, ** p <0.001; where Figure 1B shows the effect on fecal secretory IgA levels, expressed as μg / ml faecal water; where Figure 1C shows the effect on relative expression of pro-inflammatory cytokines, statistical differences between groups: * p = 0.045; where Figure 1D shows the effect on relative expression of anti-inflammatory cytokines, statistical differences between groups: ** p = 0.01; and where Figure 1E shows the effect on circulating LPS, expressed in EU / ml, of statistical differences between the groups: p = 0.03.
Figures 2A to 2E show graphs illustrating the effect of inulin, IAXOS and various compositions comprising inulin and AXOS according to the embodiments of the invention on different in vitro fermentation characteristics: where Figure 2A shows the effect on the half-life of the asymptotic gas production (T / 2), expressed in h; where Figure 2B shows the effect on total SCFA, expressed in mM / g dry matter; where Figure 2C shows the effect on acetate, expressed in mM / g dry matter; where Figure 2D shows the effect on propionate, expressed in mM / g dry matter; and where Figure 2E shows the effect on butyrate, expressed in mM / g dry matter. The significant statistical differences are indicated as follows: (*) 0.05 <p <0.1 depending on the inulin, * p <0.05 depending on the inulin, ** p <0.01 depending inulin, (&) 0.05 <p <0.1 depending on the AXOS, & p <0.05 depending on the AXOS, && p <0.01 depending on the AXOS.
Figures 3A and 3B show the HPSEC molecular weight profiles of AXOS samples used in Example 1 (Figure 3A) and Example 2 (Figure 3B). The column is a SUPELCO G-3000. The elution volumes of the dextran standards having a molecular weight of 1000 Da, 5000 Da, 12 000 Da and 50 000 Da (the latter standard only relates to Figure 3B) are indicated by a symbol "X" on the right. to the left.
Figures 4A to 4H show graphs illustrating the effects of inulin, AXOS and a mixture of 80% inulin and 20% AXOS according to the embodiment of the invention on the characteristics In an animal model: Figure 4A shows the effect on the evolution of animal weight, expressed in g; where Figure 4B shows the effect on the final body weight of the animals, expressed in g; where Figure 4C shows the effect on subcutaneous adipose tissue mass, expressed in g / 100 g total mass; where Figure 4D shows the effect on visceral adipose tissue mass, expressed in g / 100 g total mass; where Figure 4E shows the effect on the weight of the anterior tibialis muscle, expressed in g / 100 g of total weight; where Figure 4F shows the effect on soleus muscle weight, expressed in g / 100 g total weight, where Figure 4G shows the effect on leptin level in fasting blood, expressed in ng / ml, where Figure 4H shows the effect on the level of high sensitivity reactive C proteins (CRP-hs), expressed in mg / l. In all FIGS. 4A to 4H, "SH" refers to sham-operated rats, "OVX" refers to ovariectomized rats, "base" refers to a basic diet, "test" refers to an obesogenic test diet. "AXOS" means a preparation containing 7.5% of AXOS, "inulin" means a preparation containing 7.5% of inulin and "AXOS + inulin" a preparation containing 5.625% of inulin and 1.875% of AXOS . In each Figure, groups with the same letter are not significantly different (based on a statistical significance threshold of p <0.05).
Figure 5A shows a chromatogram of high pH anion exchange chromatography with pulse amperometric detection (HPAEC-PAD) of the AXOS sample used in Example 4, performed with a Dionex DX500 line using a CarboPAc PA100 column and a CarboPAc PA100 precolumn.
Figure 5B is a chromatogram of a high performance diffusion exclusion chromatography (HPSEC) of the AXOS sample used in Example 4. The column is a KS-804 (8, 0 x 300 mm) equipped with a KS-G precolumn (6.0 50 mm). The elution volumes of the pullulan standards having molecular weights of 788,000, 404,000, 212,000, 112,000, 47,300, 22,800, 11,800 and 5,900 daltons and stachyose (667 daltons), maltotriose (504 daltons), sucrose (342 daltons) and glucose (180 daltons) are indicated by a "+" symbol from left to right, in descending order of molecular weight.
The dotted line separating the area under the curve into 2 equal parts determines the mean DP ~ 6.
Description of the invention
The present invention is now described in more detail. In the following paragraphs, different aspects of the invention are defined in more detail. Unless otherwise indicated, each aspect so defined may be combined with any other aspect. In particular, any features indicated as being preferred or advantageous may be combined with any other characteristic indicated as being preferred or advantageous.
Thus, the present invention relates to a composition comprising inulin and arabinoxylan for reducing, preventing and / or treating inflammation. In one embodiment, said inflammation is systemic inflammation. The present invention preferably relates to a composition comprising inulin and arabinoxylan, wherein said arabinoxylan is partially hydrolysed arabinoxylan and wherein the ratio of said inulin to said partially hydrolyzed arabinoxylan and / or arabinoxylan is included between 65% / 35% by weight and 90% / 10% by weight, for use to reduce, prevent and / or treat inflammation.
Any reference to "an embodiment" in this description means that a particular feature, structure or feature described with respect to the embodiment is included in at least one embodiment of the present invention. Thus, the use of the expression "in one embodiment" in several places of this description is unnecessary because it designates the same embodiment. In addition, particular features, structures, or features may be combined in any suitable manner, as would be readily apparent to those skilled in the art upon reading this description, in one or more embodiments. On the other hand, although some embodiments described herein include some but not other features included in other embodiments, the combinations of features of different embodiments are intended to be within the scope of the invention. invention, and form different embodiments, as would be understood by those skilled in the art.
As used in the description and the appended claims, the singular forms "a" and "la" include several referents unless otherwise indicated. By way of example, an "arabinoxylan oligosaccharide" refers to an arabinoxylan oligosaccharide or more than one arabinoxylan oligosaccharide.
As used herein, the terms "about" and "approximately" when referring to a measurable value such as a parameter, quantity, duration and the like are intended to encompass variations of and from the specified value, in particular variations of +/- 10% or less, preferably of + 1-5% or less, more preferably of +/- 1% or less, and still more preferably of +/- 0.1% or less, from and from the specified value, to the extent that these variations are appropriate to the realization of the described invention. It is to be understood that the value to which the "about" or "approximately" modifier refers is also specifically, and preferably, described.
As used herein, the term "monosaccharide" refers to a single sugar unit which is the oligo- and polysaccharide building block. Non-limiting examples of monosaccharides include glucose, fructose, xylose, arabinose, galactose, mannose and the like.
As used herein, the term "carbohydrate" refers to a polyhydroxyaldehyde (aldose) or a ketone (ketosis) or a substance that produces one or more of these substances by hydrolysis.
As used herein, the term "degree of polymerization" or "(DP)" refers to the number of monosaccharide residues present in an oligo- or polysaccharide. The parameter average degree of polymerization is also often used. The degree of polymerization is a measure of molecular weight (MW). The DP can be calculated as a ratio of the total MW of the polymer or oligomer to the MW of the repeating units.
The average degree of polymerization (DP moy) of a polydispersed mixture of oligo- or polysaccharides is the average of the degree of polymerization (DP) of all the molecules present in this mixture of saccharides. The average degree of polymerization can be calculated on the basis of the number of molecules for each DP: DPn moy (1) (or average degree of polymerization in number), or on the basis of the mass of the molecules for each DP: DPW moy ( 2). In the present patent application, unless otherwise indicated, the average degree of polymerization is considered to be the DPn avm and can be calculated as described herein.
(1) The average DPn can be determined as a total number of moles of monomers after complete hydrolysis divided by the number of moles present in the mixture before hydrolysis. For example, for arabinoxylan, the number of moles of monomers can be calculated as the mass of arabinoxylan divided by 132 (molecular weight of xylose and arabinose residues). The number of moles before hydrolysis can be determined by the number of xylose reducing ends, as explained in Courtin et al, 2000 (Courtin et al., 2000, J. Chromatography A866, 97-104). For native inulin or enzymatically synthesized oligofructose from sucrose, DPn moy can be calculated by dividing the total amount of glucose and fructose (after hydrolysis) by the total amount of glucose (after hydrolysis) of this inulin. For partially hydrolysed inulin, DPn moy can be calculated from the results of high performance anion exchange chromatography with pulse amperometric detection analysis (HPAEC-PAD or Dionex).
(2) Examples of suitable assay methods for the determination of DPn moy are described in the literature, including, for example, in ΙΈΡ 1,758,470 attached herein for reference.
As used herein, the term "polysaccharide" refers to a carbohydrate composed of a large number (DP> 20) of monosaccharides linked by glycosidic linkages. Non-limiting examples of naturally occurring polysaccharides are plant cell wall polysaccharides such as cellulose, pectins, arabinans / arabans, arabinoxylans, xylans, arabinogalactans, xyloglucans, beta-glucans or other polysaccharides. such as starches, galactomannans, mannans, arabinogalactans and fructans.
As used herein, the term "oligosaccharide" refers to a carbohydrate composed of a delimited number of monosaccharides linked by glycosidic linkages; the DP is generally between 2 and 20. Non-limiting examples of naturally occurring oligosaccharides are sucrose, cellobiose, raffinose, xylooligosaccharides, fructo-oligosaccharides and galacto-oligosaccharides.
As used herein, the term "fermentable fiber" refers to a mixture of non-digestible oligosaccharides and / or non-digestible polysaccharides, i.e., that escape digestion and / or absorption into the body. upper digestive tract of humans, mainly because of the configuration of their osidic bonds. They thus arrive in the large intestine where they can be partially or totally fermented by the endogenous microflora. This fermentation process produces short chain gases and / or fatty acids such as, for example, acetate, propionate and butyrate.
As used herein, the term "cereals" refers to cereal crops including, but not limited to, wheat, oats, rye, barley, sorghum, maize, rice, millet and triticale.
As used herein, the term "prebiotic" refers to a non-digestible food ingredient that positively impacts the host by selectively stimulating the growth and / or activity of a bacterium or a limited number of bacteria in the colon, and thus improves the health of the host. (Gibson & Roberfroid, 1995, J Nutr 125, 1401-1412.).
As used herein, the term "prebiotic effect" refers to the selective stimulation of the growth and / or activity of a bacterium or a limited number of bacteria in the colon, thereby improving the health of the host. An example of a marker suitable for a prebiotic effect is the selective stimulation of bifidobacteria and / or lactobacilli. Non-restrictive examples of improving the health of an individual include deconstipation, improvement of intestinal transit, improvement of mineral absorption, improvement of lipid metabolism and / or improvement of satiety . In the context of the last two definitions, "host" should be understood to mean a human or an animal.
The term "host", "individual" or "subject" as used herein includes, inter alia, a subject, a patient, a target, a host or recipient, regardless of whether the individual is a human or an animal other than humans, including an avian species. The term "host", "individual" or "subject" includes, therefore, a human, a primate other than human (eg, gorilla, marmoset, African monkey), a farmed animal (e.g. , sheep, cow, pig, horse, donkey, goat), a laboratory animal (eg, rat, rabbit, guinea pig, hamster), a pet (eg, dog, cat), a wild animal captive (eg, fox, deer, game) and an avian species, including backyard birds (eg, chickens, ducks, geese, turkeys). However, the preferred individual is a human. However, to the extent that the present invention extends to an animal model, the individual may be a mouse, a rat, a pig, a sheep, a primate other than humans, or another animal other than the animal. 'human.
As used herein, the term "food additive" refers to an ingredient, additive, component or supplement suitable for incorporation into food or feed.
As used herein, the term "functional food additive" refers to an ingredient, additive, component or supplement suitable for incorporation into human or animal foods that provide technical, nutritional and / or health benefit to humans. such as, for example, a prebiotic effect and / or other nutritional / health benefit closely related to the selective stimulation of certain colon bacteria, in particular for the deconstipation, the improvement of the intestinal transit, the improvement of the mineral absorption, improvement of lipid metabolism and improvement of the regulation of blood glucose / insulinemia, or improvement of satiety. The "functional food additive" can be added in different types of foods such as, but not limited to, functional foods, diet foods and dietary supplements.
As used herein, the term "arabinoxylan" refers to a mixture of polysaccharides and / or oligosaccharides of beta-linked (1-4) linked xylose units. The xylose units may be substituted at different degrees in 0-2 and / or 0-3 by arabinose units. Arabinoxylans are therefore branched fibers. Ferulic acid, galactose and / or glucuronic acid may also be present in the structure. Arabinoxylan is also classified as hemicellulose.
In one embodiment, said arabinoxylan may comprise or consist of products derived from the partial hydrolysis of arabinoxylan, referred to herein as partially hydrolysed arabinoxylan. As used herein, the terms "partially hydrolysed arabinoxylan" or "(AXOS)" refer to a mixture of poly- and / or oligosaccharides of xylose units linked by beta (1-4) and substituted linkages. to different degrees in 0-2 and / or 0-3 by arabinose units. Ferulic acid, galactose and / or glucuronic acid may also be present in the structure. The term "partially hydrolysed arabinoxylan" is intended to have the same meaning as "AXOS". Both terms are used interchangeably here.
Suitable methods for the preparation and partial hydrolysis of the partially hydrolysed arabinoxylan to arabinoxylan include partial hydrolysis of arabinoxylan by chemical (e.g., acid or alkaline), enzymatic, physical (heat, pressure) or mechanical (ball milling, wet grinding), before or after removal (if necessary) and further purification (removal of most proteins, ashes and other impurities, ...) by standard techniques known from those skilled in the art, in order to obtain a product containing at least 50% (calculated by multiplying 0.88 by the sum of the arabinose and xylose content after complete acid hydrolysis) of the partially hydrolysed arabinoxylan on the dry matter . The finished product can be a liquid or a powder. In one embodiment, said arabinoxylan is partially hydrolysed by endoxylanase under appropriate conditions.
As used herein, the term "degree of substitution" for arabinoxylan refers to the ratio of arabinoxyl subunits to xylose subunits in partially hydrolysed arabinoxylan and / or arabinoxylan. The term "degree of substitution" for arabinoxylan is used interchangeably with "A / X ratio" or "arabinose / xylose ratio". The A / X ratio can be calculated by measuring, by HPLC, the content of arabinose and xylose in the analyzed arabinoxylan sample, after complete hydrolysis of the arabinoxylan under hydrofluoric acid or hot sulfuric acid (for example: a concentration of 1M sulfuric acid for 1 hour at 100 ° C).
As used herein, the term "inulin" refers to a mixture of oligo- and / or polysaccharides of fructose capable of having terminal glucose. Inulins belong to the class of fibers known as fructans. In one embodiment, the inulin may be represented, according to the terminal carbohydrate unit, by the general formulas GFn and Fm, where G represents a glucose unit, F represents a fructose unit, n is an integer representing the number of fructose units linked to the terminal glucose unit, and m is an integer representing the number of fructose units linked to each other in the sugar chain. Inulins usable in the present invention include inulins having a terminal glucose, which are also called alpha-D-glucopyranosyl- [beta-D-fructofuranosyl] (n-1) -D-fructofuranosides, as well as inulins without glucose, which are also called beta-D-fructopyranosyl- [D-fructofuranosyl] (n-1) -D-fructofuranosides. The inulins which can be used in the present invention can also include the products resulting from the hydrolysis of inulins such as oligofructoses, which are fructose oligomers having a degree of polymerization (DP) of <20. They may also include fructose oligomers terminating in terminal glucose having a DP of 3 to 5 and synthesized from sucrose. Suitable oligosaccharide chains of vegetable origin inulin usable in the invention may have a degree of polymerization (DP) ranging from 3 to about 100. The inulin may be a liquid or powdery product.
As used herein, the term "short chain fatty acids" or "AGCC" refers to a subgroup of fatty acids having aliphatic tails of less than six carbon atoms. They include, but are not limited to, acetic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid, valeric acid, caproic acid, lactic acid and the like. succinic acid.
As used herein, the term "inflammation" refers to the complex biological response of vascular tissues to harmful stimuli, including pathogens, damaged cells or irritants. Inflammation can be acute or chronic.
Acute inflammation is the body's initial response to harmful stimuli and is the result of increased movement of plasma and blood leukocytes in the injured tissues. A series of biochemical events spreads and produces the inflammatory reaction, involving the local vascular system, the immune system and various cells in the injured tissue. Prolonged inflammation, known as chronic inflammation, results in a progressive remodeling of the type of cells present at the site of inflammation and is characterized by simultaneous destruction and healing of the tissue resulting from the inflammatory process. Although the processes involved are identical to local or tissue inflammation, "systemic inflammation" or "IS" is not limited to a particular tissue but involves the endothelium and other organ systems. Systemic inflammation is the result of the release of proinflammatory cytokines from immune cells and chronic activation of the innate immune system. As used herein, the term "systemic" refers to the affection of the whole body. According to the present invention, the disorders associated with systemic inflammation are selected from the group consisting of insulin resistance; atherosclerosis, ischemic heart disease, stroke; metabolic syndrome; obesity; type 2 diabetes; autoimmune diseases such as rheumatoid arthritis and lupus; allergic diseases such as allergic rhinitis, allergic conjunctivitis, asthma, eczema, urticaria, contact dermatitis, systemic allergic reaction (anaphylaxis); infections such as kidney or bladder infections, gall bladder infection, chronic tonsillitis, diverticular disease; acute or chronic infectious or parasitic processes (with the exception of infectious or parasitic intestinal processes), including viral, bacterial or fungal infection; Gram-negative sepsis, endotoxin-induced shock, systemic inflammatory reaction syndrome (SIRS), or multiple organ failure syndrome. In one embodiment, said systemic inflammation is caused by disorders selected from the group consisting of acute or chronic infectious or parasitic processes, including viral, bacterial or fungal infection; Gram-negative sepsis, the shock induced by endotoxin. In a preferred embodiment, said systemic inflammation is caused by disorders selected from insulin resistance, obesity, metabolic syndrome and / or type 2 diabetes, preferably obesity.
An example of local inflammation (as opposed to systemic infection) is gastrointestinal inflammation, including diarrhea, inflammatory bowel disease, Crohn's disease, enterocolitis, ulcerative colitis, allergic colitis, irritable bowel syndrome, pouchitis, post-infectious colitis, Clostridium difficile-associated diarrhea, Rotavirus-associated diarrhea or postinfectious diarrhea, or diarrheal disease caused by an infectious agent such as E. coli. coli.
As used herein, the term "lipopolysaccharide" (LPS) is a component of the cell wall of Gram-negative bacteria, which may be responsible for initiating a series of highly complex, sequential events resulting in damage. several organs, including the liver and lung. LPS can contribute to the initiation and development of inflammation, insulin resistance and fat storage.
As used herein, "%" refers to "% by weight expressed on dry matter". The% can be calculated on the total composition according to the present invention. Alternatively, the% can be calculated from the ratio of two or more compounds of a mixture.
The present invention relates to a composition comprising inulin and arabinoxylan and its use for preventing, reducing and / or treating inflammation, for example systemic inflammation. As used herein, the term "comprising" means that the composition contains at least inulin and arabinoxylan. Additional compounds, ingredients and products may or may not be present in this composition. Non-limiting examples of additional ingredients include other fermentable fiber, carbohydrates, proteins, fats, minerals and vitamins. In a particular embodiment, the composition of the present invention may also comprise arabinogalactan peptides.
As such, the invention also encompasses a composition of inulin and arabinoxylan and its use for preventing, reducing and / or treating inflammation, preferably systemic inflammation. Preferably, the present composition is used to prevent, reduce and / or treat systemic inflammation. Accordingly, the present invention also relates to the use of a composition comprising inulin and arabinoxylan for the preparation of a food or medicine for preventing, reducing and / or treating inflammation, preferably to prevent, reduce and / or treat systemic inflammation. The present invention also relates to a method for preventing, reducing and / or treating systemic inflammation or inflammation comprising administering a physiologically or therapeutically effective amount of a composition comprising inulin and arabinoxylan to an individual in need.
As used herein, the term "therapeutically effective amount" of said composition described above refers to the amount of said composition required to achieve the desired therapeutic and / or prophylactic effect. The effective amounts can be measured and expressed in g / day.
As used herein, the term "physiologically effective amount" of said composition described above refers to the amount of said composition required to achieve the desired physiological effect. The effective amounts can be measured and expressed in g / day.
The inventors have surprisingly discovered that inulin and arabinoxylan exert synergistic effects on the reduction, prevention and / or treatment of inflammation, in particular of systemic inflammation. In a particular embodiment, the present invention provides a composition comprising inulin and arabinoxylan, wherein said inulin and said arabinoxylan are present in synergistic amounts. In one embodiment, disorders associated with systemic inflammation are selected from the group consisting of acute or chronic infectious or parasitic processes, including viral, bacterial, or fungal infection; Gram negative sepsis, and endotoxin-induced shock. In another embodiment, the disorders associated with systemic inflammation are selected from the group consisting of insulin resistance, obesity, metabolic syndrome and / or type 2 diabetes. Accordingly, the compositions provide to animals and humans the ability to better withstand stress, inflammation and / or immune challenge. In particular, the present inventors have found that a composition comprising inulin and arabinoxylan synergistically attenuates both the increase of proinflammatory cytokines (such as TNF-σ, IL-1.5, IL-1, 8, IL-12, IFN-y) and suppression of anti-inflammatory cytokines (such as IL-10, IL-4, IL-13), after challenge with LPS. LPS challenge may be the result of certain Gram-negative bacteria that are naturally present in the gut or that are introduced at a certain time and cause an infection. Alternatively, the origin of the LPS may be external, for example ingestion of contaminated food. While local (that is, in the gut) or systemic (ie, in the blood) LPS suppress anti-inflammatory cytokines and promote pro-inflammatory cytokines, these compositions at least partially reverse this situation or at least partially prevent this situation.
As used herein, the term "synergism" or "synergy" refers to two or more agents, working together to produce a result that can not be obtained by any of the agents individually. This term is used to describe a situation in which different entities cooperate advantageously in order to obtain a final result. As used herein, the term "synergistic amounts" or "synergistic amounts" refers to amounts of inulin and arabinoxylan which together provide a more pronounced effect than either of them alone, or allow to obtain a greater effect than for the sum of each of them alone.
The inventors have also discovered that a composition comprising inulin and arabinoxylan can synergistically decrease the concentration of LPS in the blood and thereby reduce systemic inflammation. The reduction of inflammation offers the possibility of combating, preventing, reducing and / or treating obesity, metabolic syndrome and / or type 2 diabetes. Accordingly, the invention also relates to a composition comprising inulin and arabinoxylan for the reduction, prevention and / or treatment of obesity, metabolic syndrome and / or type 2 diabetes. The present invention also relates to a composition comprising inulin and arabinoxylan and / or AXOS for use in the prevention, treatment and / or mitigation of insulin resistance, obesity, metabolic syndrome and / or type 2 diabetes preferably in the prevention, treatment and / or mitigation of obesity, wherein said arabinoxylan is partially hydrolysed arabinoxylan and wherein the ratio of said inulin to said arabinoxylan and / or said arable partially hydrolyzed binoxylan is from 65% to 35% by weight to 90% to 10% by weight. The invention also relates to the use of a composition comprising inulin and arabinoxylan for the preparation of a food, a food supplement or a medicament for reducing, treating and / or preventing The invention also relates to a method for reducing, preventing and / or treating obesity, metabolic syndrome and / or type 2 diabetes comprising the administration of a physiologically or therapeutically effective amount of a composition comprising inulin and arabinoxylan in an individual in need thereof.
The inventors have also discovered that a composition comprising inulin and arabinoxylan, in particular inulin and arabinoxylan in an inulin / arabinoxylan ratio of between 65% / 35% by weight and 95% / 5% by weight, preferably between 65% / 35% by weight and 90% / 10% by weight, synergistically stimulates the production of short chain fatty acids (SCFA), in particular propionate and butyrate. The inventors have also discovered that a composition comprising inulin and arabinoxylan, in particular inulin and arabinoxylan in an inulin / arabinoxylan ratio of between 65% / 35% by weight and 95% / 5% by weight, preferably between 65% / 35% by weight and 90% / 10% by weight, synergistically reduces the adipose tissue mass. Therefore, the present invention also relates to the composition as such as well as the use of a composition comprising inulin and arabinoxylan as a food additive, functional additive and / or prebiotic.
In one embodiment, the arabinoxylan useful in the present invention may comprise partially hydrolysed arabinoxylan. The average DP in the appropriate arabinoxylan number and / or partially hydrolysed arabinoxylan that can be used in the present composition is preferably less than 50, for example between 2 and 50, for example between 5 and 50, for example between 2 and 40, by example between 5 and 40, for example between 2 and 30, for example between 5 and 30, for example between 10 and 30, for example between 15 and 30, for example between 20 and 30, for example between 2 and 20, for example between 5 and 20, for example between 5 and 15, for example between 2 and 15. In another embodiment, the appropriate average number of arabinoxylan DP used in the present composition is preferably between 5 and 40 and more preferably more preferably between 20 and 40.
In one embodiment, the arabinoxylan useful in the present invention contains more than 10% by weight of molecules having a DP> 100.
In a preferred embodiment, the partially hydrolysed arabinoxylan and / or arabinoxylan used in the present composition has an average molecular weight (MW) of less than 400 kilodaltons (kDa), for example between 400 daltons (Da) and 400 kDa. for example between 400 Da and 300 kDa, for example between 400 Da and 200 kDa, for example between 400 Da and 7 kDa, and for example between 400 Da and 4 kDa.
In a particular embodiment, the partially hydrolysed arabinoxylan and / or arabinoxylan used in the present composition has an average degree of substitution of at least 0.05, for example 0.06, 0.07, 0.08. , 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, preferably from minus 0.2, for example at least 0.3, for example at least 0.4, for example at least 0.5, for example between 0.5 and 0.9, for example at least 0.6, for example between 0.1 and 1.2, for example between 0.1 and 0.9, for example between 0.2 and 0.9, for example between 0.2 and 0.5, for example between 0.25 and 0.25. and 0.35.
In a particular embodiment, the inulin that can be used in the present composition has a mean DP in a number of less than 50, for example between 2 and 50, for example between 2 and 40, for example between 2 and 30, for example between 5 and 50. and 30, for example between 5 and 20, for example between 5 and 15 and for example about 10.
In a particular embodiment, the present composition comprises at least 65% by weight of inulin, for example at least 70% by weight, for example at least 80% by weight, for example at least 90% by weight, for example 73% by weight, for example at least 74% by weight and for example about 75% by weight.
In a particular embodiment, the present composition comprises at least 5% by weight of partially hydrolysed arabinoxylan and / or arabinoxylan, for example at least 10% by weight of partially hydrolysed arabinoxylan and / or arabinoxylan, for example at least 15% by weight of partially hydrolysed arabinoxylan and / or arabinoxylan, for example at least 20% by weight of partially hydrolysed arabinoxylan and / or arabinoxylan, for example at least 30% by weight of arabinoxylan and and / or partially hydrolysed arabinoxylan, for example about 35% by weight of partially hydrolysed arabinoxylan and / or arabinoxylan, for example at least 23% by weight of partially hydrolysed arabinoxylan and / or arabinoxylan and, for example, about 25% by weight of partially hydrolysed arabinoxylan and / or arabinoxylan.
In another embodiment, the ratio of inulin to partially hydrogenated arabinoxylan and / or arabinoxylan in the present composition may be from 65% to 35% by weight to 90% to 10% by weight. between 65% / 35% by weight and 85% / 15% by weight, for example between 70% / 30% by weight and 80% / 20% by weight, for example between 73% / 27% by weight and 77% by weight. / 23% by weight, for example about 80% / 20% by weight and for example about 75% / 25% by weight.
In one embodiment, the inulin useful in the composition may be derived from or isolated from or obtained from a known natural source of inulin at that time, or may be synthesized enzymatically from sucrose, or may be commercially available inulin. In one embodiment, the inulin is derived from, or is isolated from, helene, dandelion, dahlia, wild yam, artichoke, Jerusalem artichoke, chicory, bulbous cowpea, burdock, onion, garlic, agave, earth pear, banana, leek, asparagus or quamash. In one embodiment, the inulin is a fiber (predominantly linear). Preferably, the inulin is from, or is isolated from, chicory or Jerusalem artichoke. The commercial inulin suitable for use in the invention may be chosen from the group comprising Fibruline® Instant, Fibruline® XL, Fibruline® DS, Fibruline® S2, Fibrulose® F97, ... (Cosucra-Warcoing Group, Belgium) , Frutafit® IQ, Frutafit® HD, Frutafit® TEX,
Frutafit® CLR, Frutafit® L90, Frutafit® L85, ... (Sensus, The Netherlands), Orafti® ST, Orafti® GR, Orafti® LGI, Orafti® HSI, Orafti® P95, Orafti® L85, Orafti® L60 , Orafti® synergyl, Orafti® HP, ... (Beneo-Orafti, Belgium), Actilight® 950P, Actilight® 950S, Actilight® 850S, ... (Syral, France).
In a preferred embodiment, the inulin which can be used in the composition comes from chicory or Jerusalem artichoke and has a mean DP of between 6 and 25.
In one embodiment, said partially hydrolysed arabinoxylan and / or arabinoxylan used in the composition may be from, or be isolated from or obtained from, any natural source of arabinoxylan or may be commercially available arabinoxylan. In one embodiment, said partially hydrolysed arabinoxylan and / or arabinoxylan is derived from, or is isolated from, plants, preferably cereals or peas. For example, the appropriate arabinoxylan and / or partially hydrolysed arabinoxylan may be derived from or isolated from wheat, rye, barley, maize, peas or oats, and preferably, said arabinoxylan and / or or partially hydrolysed arabinoxylan is derived from, or is isolated from, wheat. For example, said partially hydrolysed arabinoxylan and / or arabinoxylan is from, or is isolated from, wheat bran. For example, said partially hydrolysed arabinoxylan and / or arabinoxylan is from, or is isolated from, the side fraction of a starch and gluten separation process. Suitable commercial products of partially hydrolysed arabinoxylan for use in the invention may be, for example, Opti'flor® (DF3 SAS, France) and Xylooligo®-95P (Suntory, Japan).
The composition of the present invention may be useful in providing technical, nutritional and / or health benefits to an individual in need. The composition may be used for selective stimulation of growth and / or activity of the gastrointestinal microflora. In another embodiment, said composition may also be used to deconstrict, manage weight, improve intestinal transit, improve mineral absorption, improve lipid metabolism, and / or improve blood glucose / insulin regulation. The present composition can also be used to reduce the risk of heart disease, type 2 diabetes, obesity and / or metabolic syndrome, to effect immunomodulation, prevent cancer, have a positive impact on hepatic encephalopathy and reduce inflammation. The present composition is also particularly useful for improving satiety.
The composition according to the invention may be added to a food, for example a functional food, a dietary food and / or a food supplement, as a food additive, in particular a functional food additive. The present invention also relates to a process for the preparation of a food product, a beverage or a food supplement, comprising the steps of: (a) providing a composition according to the present invention and (b) formulating said composition in a food product, a food, a drink or a food supplement.
The present invention also relates to a food product containing the composition according to the present invention, as well as a food containing the same composition, a beverage containing the same composition and a food supplement containing the same composition.
The composition of the invention can be used as a food additive in the production of a food or beverage, or as a base for a dietary supplement. In one embodiment, the food, drink or complement comprises between 0.1 and 10 g of the composition according to the present invention by portion of said food, said beverage or said supplement. The present invention also relates to the food, beverage or complement comprising between 0.1 and 10 g of the composition according to the present invention, by portion of said food, said beverage or said supplement, for use in reducing, preventing and / or treat inflammation. In a preferred embodiment, the food, drink or complement comprises between 0.5 and 5 g of the composition according to the present invention by portion of said food, said beverage or said supplement. In an even more preferred embodiment, the food, beverage or complement comprises between 1 and 4 g of the composition according to the present invention by portion of said food, said beverage or said supplement.
For pharmaceutical use, the compositions of the invention may be formulated as a pharmaceutical preparation comprising partially hydrolysed inulin and arabinoxylan and / or arabinoxylan and at least one carrier, diluent or a pharmaceutically acceptable excipient and / or adjuvant, and optionally one or more other pharmaceutically active compounds. Such a formulation may be in a form suitable for oral administration.
In one embodiment, the present composition may optionally be combined with at least one pharmaceutically acceptable carrier for oral administration. When combined with a carrier, the weight percentage of the carrier in the total composition can be between 1 and 85%. Typical supports are food and water. If a soluble fiber is used, the combination of an aqueous carrier and the fiber will be a solution. If an insoluble fiber is used, the combination of an aqueous carrier and the fiber will be a suspension. The compositions may comprise an inert diluent or a food carrier. They can be embedded in gelatin capsules or compressed into tablets. For oral therapeutic administration, the composition may be incorporated with excipients and used in the form of tablets, lozenges, suppositories or capsules. Binding agents and / or pharmaceutically compatible adjuvants may be added to the composition. The tablets, pills, capsules, lozenges and the like may contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose; a disintegrant such as alginic acid, Primogel or corn starch; a lubricant such as magnesium stearate or Sterotes; a slipper such as colloidal silica; a sweetener such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate or orange flavoring. When the unit dosage form is a capsule, it may contain, in addition to the substance of the type above, a liquid carrier such as a fixed oil. In addition, the unit dosage forms may contain many other substances which modify the physical form of the unit dose, for example, coatings of sugar, shellac or other enteric agents. The composition may be administered as a component of an elixir, suspension, syrup, cachet, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetener and certain preservatives, dyes and flavors. The composition may also be mixed with other active substances which do not interfere with the desired action, or with substances which complete the desired action.
The pharmaceutical preparations are preferably in a unit dosage form, and may be suitably packaged, for example in a box, blister, vial, bottle, sachet, ampoule or other unidose or multidose holder or container ( which may be adequately labeled), optionally with one or more records containing product information and / or instructions for use.
The present composition is generally administered in an effective amount which, when administered appropriately, is sufficient to achieve the desired physiological, therapeutic and / or prophylactic effect in the individual in whom it is administered. It should also be understood that for any particular subject, specific dosages should be adjusted as a function of time according to the individual needs and professional judgment of the person administering or supervising the administration of the compositions, and that the dosage ranges indicated here are solely given by way of example and are not intended to limit the scope or practice of the composition.
The invention is now illustrated with the aid of the following examples, which in no way limit the scope of the invention.
Examples
Example 1 Effect of a Composition Comprising Inulin and Partially Hydrolyzed Arabinoxvlane (AXOS) in an Interventional Clinical Trial 1. Materials and Methods 1.1. products
Maltodextrins (Glucidex 12DE, Roquette Frères, France) were used as placebo.
The source of inulin used in this trial was Fibruline® Instant (COSUCRA-Warcoing Group, Belgium), which is a chicory inulin with a DP ranging from 2 to 60 and a mean DP (in number) of approximately 10. Fibrulin ® Instant was a powder with a dry matter content of 96% and contained, on the dry matter, 90% of inulin.
The source of AXOS used in this experiment was Opti'flor® (DF3 SAS France) and was obtained by purification of the side fraction of a plant producing wheat starch using the three-phase decanter for separation. of the two main fractions, starch and gluten. The side fraction was purified to remove a large portion of the starch, proteins, minerals and fats, the arabinoxylan was partially hydrolyzed using an endoxylanase and the reaction mixture was concentrated and dried by atomization. The resulting AXOS sample, a powder, was characterized by a dry matter content of 95%, an AXOS content of 80% (calculated by multiplying 0.88 by the sum of the arabinose and xylose content after hydrolysis total acid) on the dry matter, an average DP of approximately 25 (calculated by dividing the DP by the area under the molecular weight distribution curve by high performance diffusion exclusion chromatography (HPSEC), by a vertical line, in two equal parts) and an A / X ratio of about 0.75. 60% of the molecular weight of the AXOS sample ranged from 1,000 to 40,000 Da, a DP of between 7 and about 300.
1.2. Topics
Sixty healthy volunteers (26 men and 34 women), average age 20 +/- 2 years, with a stable weight and a body mass index (BMI) between 18.5 and 27 kg / m2 (21 average) , participated in the experiment. The exclusion criteria were a serious pathological condition, a gastrointestinal, vesicular or pancreatic disease, an antibiotic or laxative treatment during the last 6 months preceding the study, intestinal surgery during the last 12 months preceding the study, an intolerance to orange juice, diarrhea, constipation or chronic or recurrent abdominal pain, regular absorption of drugs known to affect gastrointestinal, pancreatic or vascular function, recent gastroenteritis, diabetes, regular consumption of foods or dietary supplements enriched with pre- or probiotics during the month preceding the study. The subjects gave, in writing, their informed consent to the protocol, which was approved by the "Committee for the Protection of North-West-IV Persons" in France.
1.3. Experimental plan
A randomized, parallel, double-blind, placebo-controlled trial was applied. The volunteers were randomly assigned to the three groups that were homogeneous in terms of age and BMI. After a 2-week period of food stabilization, the volunteers ingested each day for 4 weeks two portions of a mixture of 1.5 g of inulin, 0.5 g of AXOS and 0.5 g of maltodextrins (inulin mixture group). -AXOS), 2.5 g of AXOS (AXOS group) or 2.5 g of maltodextrins (placebo group), dispersed in 125 ml of orange juice.
Three-day dietary reports were performed at the beginning and end of the four-week intervention period to calculate total calorie intake, and carbohydrate, fiber, fat, and protein intake.
1.4. Sampling of stool and blood
Stool and blood samples, taken on an empty stomach, were collected twice, on the first day of the four-week intervention period, ie after 2 weeks of food stabilization (V1), and after four weeks of ingestion of products (V2). The stool samples were taken from plastic containers and immediately stored at 4 ° C for up to 12 hours prior to extraction of the SCFAs and the necessary aliquot for IgA-s was stored at -80 ° C.
Venous blood samples were immediately taken for cytokine analyzes and the rest of the samples were centrifuged and plasma was collected and stored at -80 ° C.
1.5. Ex vivo challenge with whole blood LPS and cytokine expression
Aliquots of 1 ml of heparinized blood in tubes containing beads were incubated with 100 μl of LPS solution (0.2 ng / μl). These aliquots were incubated for 6 and 24 h at 37 ° C with gentle shaking. A duplicate of a placebo blood sample was incubated without LPS. After 6 or 24 h, depending on the activation kinetics of the cytokines, 0.5 ml of blood sample was mixed in 1.3 ml of RNAIater solution and extracted after 3 days.
RNA extraction was performed using the Ribopure Blood Kit (Applied Biosystems) according to the manufacturer's instructions. Recombinant DNA was prepared with 1 μg of RNA, using the Quantitect Reverse Transcriptase Kit (QIAGEN) according to the manufacturer's instructions. The expression of the cytokines was analyzed, with 200 ng of recombinant DNA, by Sybr Green® RT-PCR amplification according to the manufacturer's instructions (Applied Biosystems), with TNF-alpha, IFN-gamma gene primers. IL-1-beta, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12 and IL-13. The threshold amplification cycles were normalized for each sample against GAPDH (housekeeping gene) and the relative expression was expressed as a difference in expression in a LPS-induced sample relative to the expression in a control (placebo) without provocation with LPS. These analyzes were performed using the computer program REST-MCS version 2 (Pfaffl et al., 2001, Nucleic acids Research, 29, 2002-2007) and according to the formula: R = (E target) ACpCible (M0YENNE tem0in "M0YENNE V sample (E ref) ACpréf (AVERAGE control - AVERAGE sample) where R = relative expression, E target = cytokine expression, E ref = GAPDH expression, ACpcible (AVERAGE control - AVERAGE sample) = difference in amplification between the control and the sample for cytokine, ACpref (MEDIUM control - MEDIUM sample) = difference in amplification between control and sample for GAPDH.
For TNF-alpha and IL-10 only, the expression was measured at V1 and V2. For all other cytokines, expression was measured only at V2.
1.6. Biochemical analyzes
Short-chain fatty acid (SCFA) concentrations of stool samples were analyzed after water extraction from stool samples (2 g in 5 ml of deionized water), centrifugation (4500 g, 5 min) and acidification (2M sulfuric acid) supernatant at a pH of 2, using gas chromatography (GC, Hewlett Packard 5890-FID). The GC was equipped with a column packed with free fatty acids (FFAP
WCOT CP 7614 (EMS Analytical Science), 25m x 0.53mm; 1 μm film thickness) and a flame ionization detector. Nitrogen was used as a carrier gas with a ΔΡ of 5 psi. The temperature of the injector and the temperature of the detector were set at 240 and 280 ° C, respectively. The AGCC concentrations were calculated from the known concentration standards of the different acids. 4-methyl-2-hydroxy-pentanone was used as the internal standard. The SCFAs were expressed in μg / g dry matter of the stool sample.
Fecal secretory IgA concentrations in stool samples taken after 4 weeks of ingestion of products were measured with an ELISA kit ((slgA ELISA Kit K8870, Immunodiagnostik) after rinsing with buffer according to the manufacturer's instructions. expressed in μg / ml faecal water.
LPS concentrations in blood samples taken after 4 weeks of product ingestion were measured by Chromogenic LAL HIT302 (Hycult) according to the manufacturer's instructions, after dilution 1/5 in endotoxin-free water and after 5 min incubation at 75 ° C to denature the protein before reaction. Values were expressed in EU / ml.
1.7. Data analysis
Univariate statistical analyzes were performed using non-parametric tests such as the Mann Whitney or Wilcoxon test or a parametric Student test. The Pearson correlation test was used for the bivariate analyzes.
2. Results and discussion
The three-day dietary reports showed that the three study groups were homogeneous in terms of macronutrient intakes and that these intakes did not differ significantly between the beginning and the end of the four-week intervention period. The total fiber intake, not taking into account the fiber content of the test products, was 12.21 +/- 3.18 g / day for the placebo group, 12.08 +/- 2.64 g / day for the AXOS group and 11.60 +/- 3.44 g / day for the inulin-AXOS mixing group
Faecal AGCC concentrations were affected by the different treatments (Figure 1A). AXOS induced a reduction in acetate concentrations (p = 0.01) associated with an increase in butyrate concentrations (p <0.001), while the inulin-AXOS mixture significantly increased (p <0.001) the concentrations of propionate and butyrate, compared with placebo treatment. The total AGCCs were 15% higher (p = 0.028) for the inulin-AXOS mix group than for the placebo group. For the AXOS group and for the inulin-AXOS mixture group, the AGCC profile was reduced in the proportions of acetate and an increase in the proportions of propionate, and in particular butyrate, compared with the placebo group.
After four weeks of product ingestion, faecal secretory IgA levels were stable for the AXOS group and almost 70% higher for the inulin-AXOS mixture group than for the placebo group (Figure 1B). Fecal secretory IgAs are immunoglobulins secreted by the intestinal mucosal layer and these molecules are markers of improved mucosal protection of the colon against infectious diseases and opportunistic bacteria.
At the end of the four weeks of intervention (V2), blood samples were taken and the blood was challenged ex vivo with lipopolysaccharides (LPS). The results of the relative expression of pro-inflammatory cytokines (TNF-alpha, IL-1-beta, IL-8, IL-12, IFN-gamma) and anti-inflammatory cytokines (IL-10, IL-4, IL-13) are shown in Figures 1C and 1D. These results showed that, compared to the placebo group, the stimulation of pro-inflammatory cytokines by LPS tended to be attenuated for the AXOS group and even more so for the inulin-AXOS mixture group. Attenuation of IL-1-beta expression reached statistical significance (p = 0.045) only for the inulin-AXOS mixture group. On the other hand, the relative expression of TNF-alpha significantly decreased by 50% (p = 0.014) between V1 and V2 in the inulin-AXOS mixture group, which was not the case for the control (results not shown). . In addition, the suppression of anti-inflammatory cytokines by LPS was also attenuated for the fiber groups, in particular for the inulin-AXOS mixture group. A very significant effect (p = 0.01) was observed for IL-13 for the inulin-AXOS mixture group. In addition, the relative expression of IL-10 increased by 55% (p = 0.064) between V1 and V2 in the inulin-AXOS mixture group, which was not the case for the control and AXOS groups (results not illustrated). IL-2 and IL-5 were not modulated by LPS challenge (results not shown). The expression of TNF-alpha and IL-10 after challenge with LPS and measured at the beginning of the intervention period (V1) showed no significant difference between the three intervention groups at V1 (results not shown ). In summary, the present results indicate that the mixture of inulin and AXOS may at least partially counteract the inflammatory response after immune challenge (such as with LPS).
The results also indicated (Figure 1E) that circulating LPS in volunteers' blood samples at the end of the four-week intervention period (before challenge with LPS) were 30% lower (p = 0.03 ) for the inulin-AXOS mixture group than for the placebo group. LPS are components of the cell wall of Gram-negative bacteria, which may be responsible for initiating a series of highly complex, sequential events that result in damage to several organs, including the liver and lung. LPS can contribute to the initiation and development of inflammation, insulin resistance and fat storage. The results obtained thus indicate a significant reduction in the risk of systemic inflammation and endotoxemia for a mixture of inulin and AXOS. This effect was not observed for the AXOS group.
In conclusion, significantly reduced levels of circulatory LPS in the blood, together with the modulation of the balance of pro and anti-inflammatory cytokines after ex vivo challenge with LPS, confirms the potential of a synergistic mixture comprising inulin and AXOS to reduce, prevent and / or treat inflammation. The corroboration of the anti-inflammatory effect of such a mixture results in a significant increase in the concentrations of fecal butyrate and fecal secretory IgA.
Example 2: In Vitro Fermentation of Different Inulin and AXOS Mixtures 1. Materials and Methods 1.1. products
The source of inulin used in this experiment was Fibruline® Instant (COSUCRA-Warcoing Group, Belgium), as indicated in Example 1. The source of AXOS used in this experiment was Opti'flor® (DF3 SAS, France) and was obtained by purification of the side fraction of a plant producing wheat starch using the three-phase decanter for separating the two main fractions, starch and gluten. The side fraction was purified to remove a large portion of the starch, proteins, minerals and fats, the arabinoxylan was partially hydrolyzed using an endoxylanase and the mixture was concentrated and spray-dried . The AXOS sample obtained, a powder, was characterized by a dry matter content of 96%, an AXOS content of 85% (calculated by multiplying 0.88 by the sum of the arabinose and xylose content after hydrolysis total acid) on the dry matter, an average DP of approximately 37 (calculated by dividing the DP by the area under the molecular weight distribution curve by high performance diffusion exclusion chromatography (HPSEC), by a vertical line, in two equal parts) and an A / X ratio of about 0.75.
The different test substances were inulin, AXOS and three mixtures of inulin and AXOS in proportions by weight of inulin / AXOS of 90% / 10%, 75% / 25% and 50% / 50 %.
1.2. Animals
A silicone cannula was implanted in the caecum of four Landrace x Pietrain sows weighing at the beginning 30 to 35 kg. The animals were housed individually and fed an average of 2 kg of commercial diet ("Pork 2 Regular", SCAR, Herve, Belgium) per day. Drinking water was provided ad libitum. The collection of cecal samples began after an adaptation period of 3 weeks.
1.3. In vitro fermentation
An in vitro model described by Bindelle et al (2007, Animal Feed Science and Technology 132, 111-122) was used.
The inoculum used for fermentation was composed of two main elements: a buffer solution composed of salts and minerals (Menke, KH, Steingass, H. 1988. Res Res Dev 28, 7-55) and the contents of caecum taken from canned pigs. The buffer was stored under anaerobic conditions by boiling CO 2 until the syringes were filled and the contents of the caecum were diluted 20-fold in the buffer solution. The contents of the caecum were removed by means of a plastic bag attached to the tip of the cannula for about 30 minutes. The contents were mixed with 150 to 200 ml of buffer solution and the mixture was filtered through a metal filter (250 μm mesh screen) after mechanical kneading (Stomacher Lab-Blender 400, Seward Medical, Norfolk, UK). bags for 60 s.
For each series, three 200 mg samples of each test substance were placed at the end of a 100 ml Kolbenprober glass syringe. The syringes were then closed and preheated for 24 hours in an incubator at 39 ° C. 30 ml of inoculum was then added to the syringes. The initial volume was read when placing the syringes in the incubator. For each series, three syringes, containing only inoculum (controls), were used to quantify inoculum-induced gas production in the absence of substrate.
1.4. Fermentation kinetics
The volumes of gas released into the syringes were recorded hourly during the first eight hours of incubation, then after 14, 24, 48, 72 and 96 hours. At each reading, the syringes were rehomogenized by shaking. The volume of gas produced was calculated based on the initial inoculum in the syringe and the amount of test product added to the syringe. This volume was corrected for the amount of gas produced in the control syringes for each reading. The corrected gas production was then expressed in g of test substance.
1.5. Short Chain Fatty Acids (SCFA)
For this experiment, the syringes were prepared as described above. The fermentation of each test substance was stopped at half-life of the asymptotic gas production (T / 2), estimated in the previous step. At T / 2, the syringes were placed in an ice bath for at least 20 min. The contents of each syringe were then taken from a 50 ml Falcon tube, the syringes were rinsed with 2 volumes of 50 ml of deionized water and this rinse was added to the Falcon tube. The mixture was centrifuged at 12,000 x g for 20 min at 4 ° C. 5 ml of supernatant from each syringe were extracted and accumulated per test substance in a 15 ml Falcon tube. Excess supernatant was discarded. The supernatant and sediment samples were then frozen at -20 ° C. Analysis and assay of the short-chain fatty acids in the supernatant were performed by HPLC according to Bindelle et al (2007, Animal 18, 1126-1133). The results were expressed in mM / g dry matter of test substance.
The sediment samples were lyophilized to determine the non-degraded dry matter content of each test substance for each sample.
1.6. Data analysis
Gas production was modeled for each syringe according to the mathematical model of France et al (1993, J. Theor Biol 163, 99-111). In this way, inter alia, T / 2, expressed in hours, could be calculated.
The statistical analysis of the parameters was performed by an analysis of variance and a least squares means classification, using the MIXED procedure of the SAS 8.02 software (SAS Inc., Carry, NC, USA).
2. Results and discussion
An in vitro model described by Bindelle et al (2007, Animal Feed Science and Technology 132, 111-122) was used to evaluate in vitro fermentation by inulin levels, AXOS and various mixtures of inulin and AXOS in the intestines of pigs.
The results are shown in Figures 2A-2E. Inulin and AXOS as well as the various inulin-AXOS mixtures were all well fermented (Figure 2A) and produced AGCCs. When inulin and AXOS were combined in 90% / 10%, 75% / 25% or 50% / 50% weight proportions, respectively, the synergistic effects of the three mixtures on AGCC production (Figure 2B), and in particular on propionate (Figure 2D) and butyrate (Figure 2E) were obtained.
Example 3: HPSEC molecular weight distribution profiles of the AXOS samples used in Examples 1 and 2
HPSEC was performed on an HPLC system (HPLC Waters 2690 Alliance, Milford, USA) equipped with an automatic injection mechanism. All preparations were dissolved in distilled water, filtered and injected (100 μl) onto a Supelco G3000 Progel-TSK gel permeation column (Sigma-Aldrich, St. Louis, USA) (300 x 7, 8 mm, separation range: 1 x 102 to 5 x 105 Da). Elution was performed with 50 mM NaNO3 solution and 0.05% NaN3 in distilled water (0.7 ml / min, 30 ° C) and monitored with a refractive index detector ( Model 2410, Waters Corporation, Milford, USA). The molecular weight markers were dextrans having a molecular weight of 1000 Da, 5000 Da, 12 000 Da and 50 000 Da (the latter standard only relates to Figure 3B). The HPSEC molecular weight distribution profiles of the AXOS samples are shown in Figures 3A and 3B.
EXAMPLE 4 Effect of a Composition Comprising Inulin and Partially Hydrolysed Arabinoxvane (AXOS) on Rats with Systemic Inflammation 1. Materials and Methods 1.1. products
The inulin preparation used in this trial was Fibruline® Instant (COSUCRA-Warcoing Group, Belgium), which is a chicory inulin with a DP ranging from 2 to 60 and a mean DP (in number) of about 10. Fibrulin ® Instant was a powder with a dry matter content of 96% and contained, on the dry matter, 90% of inulin.
The source of AXOS used in this experiment was obtained from wheat bran. Deamidated bran was suspended in deionized water to give a total dry matter content of 10%. Then the pH adjustment to 6.0 was obtained using sulfuric acid, partial hydrolysis of arabinoxylans was obtained in a thermostatically controlled container at 50 ° C with continuous stirring for 15 hours after addition of a endoxylanase. Then, the enzyme was inactivated by boiling the suspension for 5 minutes. The supernatant containing the solubilized material was then filtered off and clarified by centrifugation. Demineralization of the clarified effluent was obtained on two ion exchangers (strong cation / weak anion). After concentration under vacuum at pH 4.5, the syrup obtained was dried by lyophilization. The resulting AXOS preparation (a powder) was characterized by a dry matter content of 96%, an AXOS content of 66% (calculated by multiplying 0.88 by the sum of the arabinose and xylose content after acid hydrolysis total) on the dry matter, an average DP of approximately 6 (calculated by dividing the DP by the area under the molecular mass distribution curve by high performance diffusion exclusion chromatography (HPSEC), by a vertical line, two equal parts) and an A / X ratio of about 0.38.
1.2. Choice of animal model and diet
The ovariectomized rat model was chosen as a model of physiological hormone deficiency (modeling of biological changes in women related to menopause) affecting lipid metabolism, oxidative stress, state of inflammation and bone health .
In order to induce further metabolic disturbances and systemic inflammation, a Western-type pro-inflammatory obesogenic diet was used.
1.3. Animals and diets
Female rats were randomly assigned to 9 groups of 8 rats fed one of the semi-purified diets. A basic diet was used, as well as a Western-type test pro-inflammatory obesogenic diet (Table 1) having (1) a high lipid content (15%) with a ratio of n-6 fatty acids / n-3 = 35 and 28% of saturated fatty acids and having an insufficient content of vitamin E (1/3 of the normal needs); (2) 15% sucrose; (3) 18% protein (casein); and (4) a relative lack of minerals (0.5% calcium and 0.05% magnesium). The inulin preparation (7.5%), the AXOS preparation (7.5%) or a mixture of inulin preparations (5.625%) and AXOS (1.875%) was replaced by an equal amount of starch in the obesogenic diet test.
Table 1: Composition of experimental diets (in%)
* Starch has been added at the expense of other ingredients, up to 100% of the diet
The rats either underwent a sham operation (SH) or were surgically ovariectomized (OVX), under anesthesia with 0.75 ml of Imalgen 1000 (Merial, Lyon, France) per kg of body weight and 0.25 ml of Ventranquil 1% (Ceva Animal Health, Libourne, France) per kg of body weight, administered intraperitoneally. During the simulated operation procedure, the ovaries were exteriorized and replaced to create a stress similar to that obtained with bilateral oophorectomy.
1.4. Experimental plan
The experimental design was carried out on 6 month old Wistar rats (8 per group) and the experiment was continued for 3 months. The animals were housed individually in iron cages, in a module maintained at 22 ° C and subjected to nycthemeral cycles of 12 h / 12 h. They had free access to water and the daily amount of food distributed was 21 g, to avoid excessive consumption of food following ovariectomy. The study was conducted in accordance with the Regional Ethics Committee (France).
The efficacy of inulin and AXOS, alone or as a mixture of 80% inulin / 20% AXOS, was tested in ovariectomized rats fed a Western-type obesogenic diet. food "test").
These experimental conditions were compared with two or more protective conditions: (1) a "basic" diet (rich in micronutrients and having a balanced rate of macronutrients) and (2) simulated human operation.
Food consumption (refusal) and weight gain were recorded regularly.
At sacrifice (at the end of the 3-month intervention period), animals fasted for 12 h were anesthetized by intraperitoneal injection as described previously. Blood from the abdominal aorta was taken either from gel (coagulation activator, Sarstedt) or EDTA tubes and immediately centrifuged (4 ° C, 5 min, 3500 g). Serum and plasma samples were then frozen at -20 ° C until used for different assays. The subcutaneous and abdominal adipose tissues, as well as the muscles (anterior tibial muscle and soleus muscle) were extracted and weighed.
1.5. Biochemical analyzes
On the animals sacrificed at the end of the study (3 months), serum leptin was analyzed (LINCO RIA kit, Millipore SAS, Molsheim, France) and the high sensitivity reactive C protein was evaluated in plasma. EDTA on a Konelab20 controller (Thermo Electro Corporation, Vantaa, Finland), using a colorimetric method.
1.6. Statistical methods
The results are expressed as mean ± SEM (standard error on the mean). The significance of the differences between the treatments was determined by two factor ANOVA analysis (XLSTAT, Addinsoft) followed by a Fisher test (LSD). Values were considered significant at p <0.05. The (parametric) Pearson correlation test was used to analyze possible correlations between the parameters.
2. Results and discussion
As expected, food consumption was significantly lower in mock animals compared to ovariectomized animals (p <0.0001). In the same way, dummy and ovariectomized animals with a high-fat diet consumed less food than those under control during the first 10 weeks (p <0.0001). ). The difference was not significant at the end of the study.
The obesogenic test diet resulted in a greater weight than that obtained with the basic diet, for sham-operated rats and ovariectomized rats (Figure 4A). All ovariectomized rats gained more weight than mock rats, indicating that oophorectomy induces some metabolic changes. The addition of AXOS and / or inulin to the test diet reduced weight gain in sham rats and ovariectomized rats. The greatest inhibition of weight gain was obtained with the mixture of inulin and AXOS, although not significant in ovariectomized rats at the end of the study (Figure 4B).
In the detailed analysis of the body composition, more particularly the adipose and muscular tissues, the differences became even clearer, as explained below.
Adipose tissue is an active endocrine organ involved in the metabolic syndrome and the regulation of inflammation. Two different types of adipose tissue were analyzed: subcutaneous adipose tissue and visceral adipose tissue. As observed for total weight, the obesogenic test diet gave a subcutaneous and visceral adipose tissue weight greater than that obtained with the basic diet, for both sham operated rats and for ovariectomized rats (Figure 4C and 4D). Oophorectomy by itself significantly increased subcutaneous adipose tissue but had less impact on visceral adipose tissue. The addition of inulin and AXOS (alone or in combination) in the test diet reduced the weight of subcutaneous and visceral adipose tissue in ovariectomized rats, but this reduction became statistically significant only for the mixture of Inulin and AXOS, achieving adipose tissue weights comparable to those obtained with the basic diet. In addition, in mock simulated rats, the added fiber in the test diet significantly reduced adipose tissue weights.
In addition, two different types of muscle mass were analyzed: the anterior tibialis muscle and the soleus muscle. Ovariectomy alone did not have a significant impact on anterior tibialis muscle mass, but the obesogenic diet significantly reduced this muscle mass in both simulated and in ovariectomized rats (Figure 4E). The addition of inulin or AXOS in the test diet increased the muscle mass of the anterior tibial muscle compared to the test diet. However, these increases were not statistically significant. Only the inulin / AXOS mixture significantly increased muscle mass as compared to the test diet, both in sham-operated rats and in ovariectomized rats, thereby restoring the muscle mass obtained with most protective basic diet (Figure 4E). Similar observations were made for the soleus muscle mass (Figure 4F), although the level of significance was not achieved.
Increased adipose tissue weights and reduced muscle weights resulting from ovariectomy and / or obesogenic test diet suggest an increase in inflammatory status. The observed reduction in adipose tissue weight and the concomitant increase in muscle weight for inulin, AXOS and in particular the inulin / AXOS mixture may indicate an anti-inflammatory effect of these fibers.
Leptin is an essential adipokine involved in the regulation of food intake and body weight, but on an empty stomach, it mainly reflects adiposity. The fasting leptin level can be considered a marker of inflammation. High levels of leptin in the bloodstream are correlated with increased inflammation in obese individuals with cardiovascular complications.
The obesogenic test diet had a considerable impact on this parameter, more than doubling the rate in both dummy rats and ovariectomized rats (Figure 4G). Oophorectomy itself has also increased leptin levels. The addition of inulin to the test diet did not have a significant impact on leptin levels in ovariectomized rats. However, the addition of AXOS, and in particular the inulin / AXOS mixture, significantly reduced leptin levels at baseline levels achieved with the basal diet in mock simulated rats. The effect was not significant in ovariectomized rats receiving the inulin / AXOS mixture. Levels of leptin were found to be strongly correlated with visceral adipose tissue weights (R2 = 0.571, p <0.0001 in the Pearson correlation test), confirming its association with overall body adiposity.
C-reactive protein (CRP) is a marker of inflammation. It is synthesized by the liver. Serum levels of inflammatory markers, particularly high-sensitivity CRP-hs, have been shown to be important predictors of increased risk of type 2 diabetes and cardiovascular disease, independent of other traditional risk factors.
As shown in Figure 4H, the hs-CRP level was not significantly affected by ovariectomy or the obesogenic diet. The addition of AXOS in the test diet did not affect the level of hs-CRP in mock animals and in ovariectomized animals. The addition of inulin alone or in combination with AXOS significantly reduced the level of CRP-hs in both groups, suggesting an anti-inflammatory effect of this fiber.
In conclusion, the fermentable fibers used in this experiment, inulin and / or AXOS, had a positive impact on adipose tissue deposits and on the inflammatory state generated by a pro-inflammatory obesogenic diet and / or a physiological hormonal deficiency inducing inflammation and metabolic disturbances. The mixture of inulin (80%) and AXOS (20%) synergistically reduced the weight of subcutaneous and visceral adipose tissue, with a concomitant reduction in leptin and CRP-hs levels, indicating an effect systemic anti-inflammatory of such a mixture.
Example 5: HPAEC-PAD and HPSEC molecular weight distribution profile of the AXOS sample used in Example 4
High pH anion exchange chromatography with HPAEC-PAD pulse amperometric detection analysis was performed on a Dionex DX500 line using a CarboPAc PA100 column and a CarboPAc PA100 precolumn both stored at 30 ° C. The flow rate was 1 ml / min. The eluent was 160 mM NaOH. A linear gradient of sodium acetate ranging from 0 to 500 mM was applied during the 90 minutes of the cycle. The samples were dissolved in water (1 g / l) and filtered through 0.22 μm before injection (25 μl).
The HPAEC-PAD profile shown in Figure 5A revealed the presence of oligomers. The monomers were eluted during the first 4 minutes of the cycle.
An HPSEC (see Figure 5B) was performed on a Waters HPLC line including a pump 515, an autosampler 717 and a refractometer 2410 as a detector. The separation was carried out using pure water as the mobile phase (1 ml / min) on a KS-804 (8.0 x 300 mm) exclusion chromatography column equipped with a KS-G precolumn ( 6.0 x 50 mm) (SHODEX, SHOWA DENKO EUROPE GmbH Konrad-Zuse-Platz, 4-81829 Munich, Germany) both stored at 70 ° C, all preparations were dissolved in distilled water, filtered and injected (20 μΙ). The retention time calibration was performed using the pullulan standard P-82 (Shodex) containing the following markers 788 000, 404 000, 212 000, 112 000, 47 300, 22 800, 11 800 and 5 900 daltons and with stachyose (667 daltons), maltotriose (504 daltons), sucrose (342 daltons) and glucose (180 daltons). The corresponding retention times are shown (cross symbols) on the graph from left to right in descending order of molecular weight (Figure 5B). The dotted line separating the area under the curve into 2 equal parts determines the mean DP ~ 6.

权利要求:
Claims (15)
[1]
A composition comprising inulin and arabinoxylan for use in reducing, preventing and / or treating inflammation, wherein said arabinoxylan is partially hydrolysed arabinoxylan and wherein the ratio of said inulin to said arabinoxylan and or the partially hydrolysed arabinoxylan is from 65% to 35% by weight to 90% to 10% by weight.
[2]
The composition of claim 1, wherein said inflammation is systemic inflammation.
[3]
3. Composition according to claims 1 or 2, wherein said inulin has an average degree of polymerization in number of less than 50.
[4]
The composition of any one of claims 1 to 3 wherein said partially hydrolysed arabinoxylan has an average degree of polymerization in a number of less than 50.
[5]
5. Composition according to any one of claims 1 to 4, wherein the average molecular weight of said partially hydrolysed arabinoxylan and / or arabinoxylan is between 400 Da and 400 kDa.
[6]
The composition of any one of claims 1 to 5, wherein said partially hydrolysed arabinoxylan and / or arabinoxylan has an average arabinose / xylose ratio of at least 0.05.
[7]
7. Composition according to any one of claims 1 to 6, wherein said inulin is obtained from a plant selected from the group consisting of helene helene, dandelion, dahlia, wild yam, artichoke , Jerusalem artichoke, chicory, bulbous cowpea, burdock, onion, garlic, agave, earth pear, banana, leek, asparagus, quamash or a mixture thereof .
[8]
The composition according to any one of claims 1 to 7, wherein said arabinoxylan is obtained from wheat, rye, barley, maize, peas, oats or a mixture thereof .
[9]
The composition of any one of claims 2 to 8, wherein said systemic inflammation is caused by disorders selected from the group consisting of insulin resistance; atherosclerosis; ischemic heart disease; stroke; metabolic syndrome; obesity; type 2 diabetes; autoimmune diseases such as rheumatoid arthritis and lupus; allergic diseases such as allergic rhinitis, allergic conjunctivitis, I asthma, eczema, urticaria, contact dermatitis, systemic allergic reaction; infections including kidney or bladder infections, gall bladder infection, chronic tonsillitis, diverticular disease; acute or chronic infectious or parasitic processes, including viral, bacterial or fungal infection; Gram negative sepsis; endotoxin-induced shock; systemic inflammatory reaction syndrome (SRIS) or multiorgan failure syndrome.
[10]
The composition according to any one of claims 1 to 9, wherein the disorders associated with systemic inflammation are selected from the group consisting of acute or chronic infectious or parasitic processes, including viral, bacterial or fungal infection; Gram negative sepsis; the shock induced by endotoxin.
[11]
The composition of any one of claims 1 to 9, wherein the disorders associated with systemic inflammation are selected from the group consisting of insulin resistance, obesity, metabolic syndrome and / or type diabetes. 2.
[12]
The composition of claim 11, wherein said disorder is obesity.
[13]
A composition comprising partially hydrolysed inulin and arabinoxylan and / or arabinoxylan, wherein the ratio of said inulin to said partially hydrolysed arabinoxylan and / or said arabinoxylan is from 65% to 35% by weight and 90% / 10% by weight.
[14]
14. Food, drink or dietary supplement comprising between 0.1 and 10 g of a composition according to any one of claims 1 to 13, for a portion of said food, said beverage or said food supplement.
[15]
15. Use of a composition according to any one of claims 1 to 13 as a food additive in the production of a food, a drink or a food supplement, which comprises between 0.1 and 10 g of said composition per portion of said food, said beverage or said food supplement.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BE1019755A3|2012-12-04|COMPOSITIONS CONTAINING MIXTURES OF FERMENTABLE FIBERS.

---

JP2021063079A|2021-04-22|Glycan therapeutics and related methods thereof

---

Samuelsen et al.2014|Effects of orally administered yeast‐derived beta‐glucans: A review

---

EP3349763B1|2021-08-11|Composition for use in microbiota modulation

---

JP5030960B2|2012-09-19|Dietary fiber preparation and administration method

---

Singh2007|Psyllium as therapeutic and drug delivery agent

---

RU2553348C2|2015-06-10|Product, containing glucomannan, xanthan gum and alginate for treatment of metabolic disorders

---

JP2006508057A|2006-03-09|Nutritional composition comprising non-glucose carbohydrate or pectin and soluble fiber

---

US10857168B2|2020-12-08|Synthetic composition for microbiota modulation

---

RU2469558C2|2012-12-20|Use of probiotics and fibres in diarrhoea

---

CN104093413A|2014-10-08|Compositions and methods for treating diabetes and/or obesity

---

BE1024968B1|2018-09-04|Composition of chitosan and chitin-glucan

---

Sharma et al.2011|Prebiotics: A review of therapeutic potential

---

US20070167395A1|2007-07-19|Compositions and methods for treating diabetes

---

US20190000873A1|2019-01-03|Prophylactic use of inulin against sinusitis

---

WO2018101102A1|2018-06-07|Postprandial gip elevation inhibitor

---

CN113194748A|2021-07-30|Human dietary supplement and method for treating digestive system and immune related disorders

---

FR3078610A1|2019-09-13|COMPOSITION OF PARTICULAR PROBIOTICS AND USE FOR REDUCING DIGESTIVE INFLAMMATORY SYMPTOMS

---

WO2020234221A1|2020-11-26|Prebiotic compositions

---

FR3078609A1|2019-09-13|COMPOSITION FOR DECREASING GLUTEN SENSITIVITY

---

Lyon2012|Dietary Fiber

---

US20140212494A1|2014-07-31|Methods of Improving Digestive Health

---

Min2013|In Vitro Analysis of Short Chain Fatty Acids and Human Fecal Microbiota Stimulated by Pectin Sources

同族专利:

---

公开号 | 公开日

---

EP2467145A1|2012-06-27|

---

US20160263145A1|2016-09-15|

---

US9364538B2|2016-06-14|

---

US20120135957A1|2012-05-31|

---

EP2467145B2|2020-02-05|

---

WO2011020853A1|2011-02-24|

---

EP2467145B1|2017-01-25|

---

ES2622091T5|2020-10-19|

---

US10660913B2|2020-05-26|

---

ES2622091T3|2017-07-05|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

WO1999061036A1|1998-05-22|1999-12-02|Ulice |Use of arabinoxylans for preparing a composition|

---

WO2002008330A1|2000-07-24|2002-01-31|Rhodia Chimie|Composition comprising at least a heteroxylan which is partly substituted by one or several hydrocolloid|

---

WO2004052121A1|2002-12-12|2004-06-24|Novartis Ag|Prebiotic compositions|

---

WO2005077391A1|2004-02-17|2005-08-25|Synbiotics Ab|New synbiotic use|

---

WO2006002495A1|2004-06-30|2006-01-12|K.U. Leuven Research And Development|Prebiotic preparation|

---

WO2008087167A2|2007-01-16|2008-07-24|Puratos N.V.|Bread with increased arabinoxylo-oligosaccharide content|

---

WO2008153377A1|2007-06-15|2008-12-18|N.V. Nutricia|Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide|

---

WO2010081913A2|2009-01-19|2010-07-22|Université De Liège Gembloux Agro-Bio Tech|A process for the production of a composition, the composition and the use thereof as food additive|

---

NL1010770C2|1998-12-09|2000-06-13|Nutricia Nv|Preparation containing oligosaccharides and probiotics.|

---

AU2007280272A1|2006-08-04|2008-02-07|Shs International Ltd|Protein free formula|CN103607910A|2011-05-04|2014-02-26|莱法科特公司|Food product comprising rye|

---

BR112013032675A2|2011-06-19|2017-08-08|Vaxine Pty Ltd|adjuvant vaccine composition comprising inulin particles|

---

US9463169B2|2011-08-17|2016-10-11|Microbiome Therapeutics, Llc|Human gastrointestinal microbiome modulating food supplement for improving blood glucose regulation|

---

US9885089B2|2012-03-05|2018-02-06|Cornell University|Flagellum and anti-flagellum antibody levels in samples as a diagnostic biomarker and therapeutic target for metabolic syndrome|

---

KR101432884B1|2012-04-27|2014-08-21|재단법인 전남생물산업진흥원|Anti-inflammatory agent containing helianthus tuberosus aerial part extracts|

---

US20150296851A1|2012-11-27|2015-10-22|Shanghai Jiao Tong University|Compositions for Balancing Gut Microbiota and the Preparation and the Uses thereof|

---

ES2402643B1|2012-12-24|2014-01-24|Universitat De Lleida|Combination of anti-cholesterolemic fiber|

---

BR112015022479A2|2013-03-12|2017-07-18|Tate & Lyle Ingredients Americas Llc|corn fiber food grade arabinoxylan product|

---

AU2016321094A1|2015-09-11|2018-03-29|Pure Fiber Limited|Low molecular weight arabinoxylans with branched oligosaccharides|

---

CN105661227A|2016-01-18|2016-06-15|徐州工程学院|Processing technology of burdock lactic acid drink|

---

US20180030403A1|2016-07-28|2018-02-01|Bobban Subhadra|Devices, systems and methods for the production of humanized gut commensal microbiota|

---

EP3897211A1|2018-12-19|2021-10-27|Cosucra Groupe Warcoing S.A.|Composition comprising chicory root and pea cell wall fiber for treating brachyspira infections|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

EP09290632|2009-08-18|

---

EP09290632|2009-08-18|

---